|
[1]
|
Waks, A.G. and Winer, E.P. (2019) Breast Cancer Treatment: A Review. JAMA, 321, 288-300. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Bianchini, G., de Angelis, C. and Licata, L. (2022) Treatment Land-scape of Triple-Negative Breast Cancer—Expanded Options, Evolving Needs. Nature Reviews Clinical Oncology, 19, 91-113. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Yin, L., Duan, J.J. and Bian, X.W. (2020) Tri-ple-Negative Breast Cancer Molecular Subtyping and Treatment Progress. Breast Cancer Research: BCR, 22, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Derakhshan, F. and Reis-Filho, J.S. (2022) Pathogenesis of Triple-Negative Breast Cancer. Annual Review of Pathology: Mechanisms of Disease, 17, 181-204. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Won, K. and Spruck, C. (2020) Triple-Negative Breast Cancer Therapy: Current and Future Perspectives (Review). International Journal of Oncology, 57, 1245-1261. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Liedtke, C., Mazouni, C. and Hess, K.R. (2008) Response to Neoadju-vant Therapy and Long-Term Survival in Patients with Triple-Negative Breast Cancer. Journal of Clinical Oncology: Of-ficial Journal of the American Society of Clinical Oncology, 26, 1275-1281. [Google Scholar] [CrossRef]
|
|
[7]
|
Kumar, P. and Aggarwal, R. (2016) An Overview of Tri-ple-Negative Breast Cancer. Archives of Gynecology and Obstetrics, 293, 247-269. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Loibl, S., Poortmans, P. and Morrow, M. (2021) Breast Cancer. The Lancet (London, England), 397, 1750-1769. [Google Scholar] [CrossRef]
|
|
[9]
|
Early Breast Cancer Trialists’ Collaborative Group, et al. (2012) Comparisons between Different Polychemotherapy Regimens for Early Breast Cancer: Meta-Analyses of Long-Term Outcome among 100,000 Women in 123 Randomised Trials. The Lancet, 379, 432-444.
https://pubmed.ncbi.nlm.nih.gov/22152853/
|
|
[10]
|
Blum, J.L., Flynn, P.J., Yothers, G., et al. (2023) Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG On-cology). Journal of Clinical Oncology, 35, 2647-2655.
https://pubmed.ncbi.nlm.nih.gov/28398846/
|
|
[11]
|
Nitz, U., Gluz, O. and Clemens, M. (2019) West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophos-phamide plus Docetaxel versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37, 799-808. [Google Scholar] [CrossRef]
|
|
[12]
|
Poggio, F., Bruzzone, M. and Ceppi, M. (2018) Platinum-Based Neo-adjuvant Chemotherapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 29, 1497-1508. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Von Minckwitz, G., Schneeweiss, A. and Loibl, S. (2014) Neoadju-vant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial. The Lancet Oncology, 15, 747-756. [Google Scholar] [CrossRef]
|
|
[14]
|
Sikov, W.M., Berry, D.A. and Perou, C.M. (2015) Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33, 13-21.
|
|
[15]
|
Zhu, Y., Hu, Y. and Tang, C. (2022) Platinum-Based Systematic Therapy in Triple-Negative Breast Cancer. Biochimica et Biophysica Acta. Reviews on Cancer, 1877, Article ID: 188678. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Wang, X.L., Chen, T., Li, C., et al. (2022) CircRNA-CREIT In-hibits Stress Granule Assembly and Overcomes Doxorubicin Resistance in TNBC by Destabilizing PKR. Journal of Hematology & Oncology, 15, 122.
https://pubmed.ncbi.nlm.nih.gov/36038948/
|
|
[17]
|
Nedeljković, M. and Damjanović, A. (2019) Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge. Cells, 8, Article No. 957. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Sissung, T.M., Baum, C.E., Kirkland, C.T., et al. (2010) Phar-macogenetics of Membrane Transporters: An Update on Current Approaches. Molecular Biotechnology, 44, 152-167.
https://pubmed.ncbi.nlm.nih.gov/19950006/
|
|
[19]
|
Sharom, F.J. (2008) ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance. Pharmacogenomics, 9, 105-127. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Yamada, A., Ishikawa, T. and Ota, I. (2013) High Expression of ATP-Binding Cassette Transporter ABCC11 in Breast Tumors Is Associated with Aggressive Subtypes and Low Dis-ease-Free Survival. Breast Cancer Research and Treatment, 137, 773-782. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Guestini, F., Ono, K. and Miyashita, M. (2019) Impact of Topoi-somerase IIα, PTEN, ABCC1/MRP1, and KI67 on Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Cancer Research and Treatment, 173, 275-288. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Das, S., Samant, R.S. and Shevde, L.A. (2013) Nonclassical Ac-tivation of Hedgehog Signaling Enhances Multidrug Resistance and Makes Cancer Cells Refractory to Smooth-ened-Targeting Hedgehog Inhibition. The Journal of Biological Chemistry, 288, 11824-11833. [Google Scholar] [CrossRef]
|
|
[23]
|
Skoda, A.M., Simovic, D. and Karin, V. (2018) The Role of the Hedgehog Signaling Pathway in Cancer: A Comprehensive Review. Bosnian Journal of Basic Medical Sciences, 18, 8-20. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Harris, L.G., Pannell, L.K. and Singh, S. (2012) Increased Vascularity and Spontaneous Metastasis of Breast Cancer by Hedgehog Signaling Mediated Upregulation of cyr61. On-cogene, 31, 3370-3380. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Kwon, Y.-J., Hurst, D.R., Steg, A.D., et al. (2011) Gli1 Enhances Migration and Invasion via Up-Regulation of MMP-11 and Promotes Metastasis in ERα Negative Breast Cancer Cell Lines. Clinical & Experimental Metastasis, 28, 437-449.
https://pubmed.ncbi.nlm.nih.gov/21442356/
|
|
[26]
|
Di Mauro, C., Rosa, R. and D’amato, V. (2017) Hedgehog Sig-nalling Pathway Orchestrates Angiogenesis in Triple-Negative Breast Cancers. British Journal of Cancer, 116, 1425-1435. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Shibata, M. and Hoque, M.O. (2019) Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer. Cancers, 11, Article No. 732. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Creighton, C.J., Li, X. and Landis, M. (2009) Residual Breast Can-cers after Conventional Therapy Display Mesenchymal as Well as Tumor-Initiating Features. Proceedings of the National Academy of Sciences of the United States of America, 106, 13820-13825. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Lee, H.E., Kim, J.H. and Kim, Y.J. (2011) An Increase in Cancer Stem Cell Population after Primary Systemic Therapy Is a Poor Prognostic Factor in Breast Cancer. British Journal of Cancer, 104, 1730-1738. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Park, S.Y., Lee, H.E., Li, H.L., et al. (2010) Heterogeneity for Stem Cell-Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer. Clinical Cancer Research, 16, 876-887.
https://pubmed.ncbi.nlm.nih.gov/20103682/
|
|
[31]
|
Ma, F., Li, H.H., Wang, H.J., et al. (2014) Enriched CD44(+)/CD24(−) Population Drives the Aggressive Phenotypes Presented in Triple-Negative Breast Cancer (TNBC). Cancer Letters, 353, 153-159.
https://pubmed.ncbi.nlm.nih.gov/25130168/
|
|
[32]
|
Zhou, S., Schuetz, J.D., Bunting, K.D., et al. (2001) The ABC Transporter Bcrp1/ABCG2 Is Expressed in a Wide Variety of Stem Cells and Is a Molecular Determinant of the Side-Population Phenotype. Nature Medicine, 7, 1028-1034.
https://pubmed.ncbi.nlm.nih.gov/11533706/
|
|
[33]
|
Vaupel, P. (2008) Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis. The Oncologist, 13, 21-26. [Google Scholar] [CrossRef]
|
|
[34]
|
Gerweck, L.E., Vijayappa, S. and Kozin, S. (2006) Tumor pH Controls the in Vivo Efficacy of Weak Acid and Base Chemotherapeutics. Molecular Cancer Therapeutics, 5, 1275-1279.
https://pubmed.ncbi.nlm.nih.gov/16731760/
|
|
[35]
|
Cosse, J.P. and Michiels, C. (2008) Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression. Anti-Cancer Agents in Medicinal Chemistry, 8, 790-797. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Kim, H., Lin, Q., Glazer, P.M. and Yun, Z. (2018) The Hy-poxic Tumor Microenvironment in Vivo Selects the Cancer Stem Cell Fate of Breast Cancer Cells. Breast Cancer Re-search, 20, 16.
https://pubmed.ncbi.nlm.nih.gov/29510720/
|
|
[37]
|
Chouaib, S., Noman, M.Z. and Kosmatopoulos, K. (2017) Hypoxic Stress: Obstacles and Opportunities for Innovative Immunotherapy of Cancer. Oncogene, 36, 439-445. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Xiang, L., Liu, Z.-H., Huan, Q., et al. (2012) Hypox-ia-Inducible Factor-2a Is Associated with ABCG2 Expression, Histology-Grade and Ki67 Expression in Breast Invasive Ductal Carcinoma. Diagnostic Pathology, 7, 32.
https://pubmed.ncbi.nlm.nih.gov/22452996/
|
|
[39]
|
Lv, Y., Zhao, S. and Han, J. (2015) Hypoxia-Inducible Factor-1α Induces Multidrug Resistance Protein in Colon Cancer. OncoTargets and Therapy, 8, 1941-1948. [Google Scholar] [CrossRef]
|
|
[40]
|
Daskalaki, I., Gkikas, I. and Tavernarakis, N. (2018) Hypoxia and Selec-tive Autophagy in Cancer Development and Therapy. Frontiers in Cell and Developmental Biology, 6, Article No. 104.
https://pubmed.ncbi.nlm.nih.gov/30250843/
|
|
[41]
|
Livasy, C.A., Karaca, G. and Nanda, R. (2006) Phenotypic Eval-uation of the Basal-Like Subtype of Invasive Breast Carcinoma. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 19, 264-271. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Tan, E.Y., Yan, M. and Campo, L. (2009) The Key Hypoxia Reg-ulated Gene CAIX Is Upregulated in Basal-Like Breast Tumours and Is Associated with Resistance to Chemotherapy. British Journal of Cancer, 100, 405-411. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Chen, X., Iliopoulos, D., Zhang, Q., et al. (2014) XBP1 Promotes Tri-ple-Negative Breast Cancer by Controlling the HIF1α Pathway. Nature, 508, 103-107.
https://pubmed.ncbi.nlm.nih.gov/24670641/
|
|
[44]
|
Lei, J., Fan, L. and Wei, G. (2015) Gli-1 Is Crucial for Hypox-ia-Induced Epithelial-Mesenchymal Transition and Invasion of Breast Cancer. Tumour Biology: The Journal of the In-ternational Society for Oncodevelopmental Biology and Medicine, 36, 3119-3126. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Klionsky, D.J. and Emr, S.D. (2000) Autophagy as a Regulated Pathway of Cellular Degradation. Science (New York, N.Y.), 290, 1717-1721. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Chen, Y., Jia, Y. and Mao, M. (2021) PLAC8 Promotes Adriamycin Resistance via Blocking Autophagy in Breast Cancer. Journal of Cellular and Molecular Medicine, 25, 6948-6962. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Wang, L., Zhang, H. and Sun, M. (2015) High Mobility Group Box 1-Mediated Autophagy Promotes Neuroblastoma Cell Chemoresistance. Oncology Reports, 34, 2969-2976. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Yang, L., Yu, Y. and Kang, R. (2012) Up-Regulated Autophagy by En-dogenous High Mobility Group Box-1 Promotes Chemoresistance in Leukemia Cells. Leukemia & Lymphoma, 53, 315-322. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Zhao, Y., Meng, Q. and Gao, X. (2017) Down-Regulation of Mediator Complex Subunit 19 (Med19) Induces Apoptosis in Human Laryngocarcinoma HEp2 Cells in an Apaf-1-Dependent Pathway. American Journal of Translational Research, 9, 755-761.
|
|
[50]
|
Liu, B., Qi, X. and Zhang, X. (2019) Med19 Is Involved in Chemoresistance by Mediating Autophagy through HMGB1 in Breast Cancer. Journal of Cellular Biochemistry, 120, 507-518. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Ng, L.F., Kaur, P. and Bunnag, N. (2019) WNT Signaling in Disease. Cells, 8, 826. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Duchartre, Y., Kim, Y.-M. and Kahn, M. (2016) The Wnt Signaling Pathway in Cancer. Critical Reviews in Oncology/Hematology, 99, 141-149.
https://pubmed.ncbi.nlm.nih.gov/26775730/
|
|
[53]
|
Liu, S., Wang, Z. and Liu, Z. (2018) miR-221/222 Activate the Wnt/β-Catenin Signaling to Promote Triple-Negative Breast Cancer. Journal of Molecular Cell Biology, 10, 302-315. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Xu, J.H., Prosperi, J.R., Choudhury, N., et al. (2015) β-Catenin Is Re-quired for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells. PLOS ONE, 10, e0117097.
https://pubmed.ncbi.nlm.nih.gov/25658419/
|
|
[55]
|
Vicens, Q. and Westhof, E. (2014) Biogenesis of Circular RNAs. Cell, 159, 13-14. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Chen, C., Zhou, Z. and Sheehan, C.E. (2009) Overexpression of WWP1 Is Associated with the Estrogen Receptor and Insulin-Like Growth Factor Receptor 1 in Breast Carcinoma. In-ternational Journal of Cancer, 124, 2829-2836. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Lee, Y.R., Chen, M. and Lee, J.D. (2019) Reactivation of PTEN Tumor Suppressor for Cancer Treatment through Inhibition of a MYC-WWP1 Inhibitory Pathway. Science (New York, N.Y.), 364, eaau0159.
|
|
[58]
|
Nechiporuk, T., Fernandez, T.E. and Vasioukhin, V. (2007) Failure of Epithelial Tube Maintenance Causes Hydrocephalus and Renal Cysts in Dlg5-/-Mice. Developmental Cell, 13, 338-350.
https://pubmed.ncbi.nlm.nih.gov/17765678/
|
|
[59]
|
Sarrió, D., Rodriguez-Pinilla, S.M., et al. (2008) Epitheli-al-Mesenchymal Transition in Breast Cancer Relates to the Basal-Like Phenotype. Cancer Research, 68, 989-997.
https://pubmed.ncbi.nlm.nih.gov/18281472/
|
|
[60]
|
Liu, J., Li, J. and Li, P. (2017) Loss of DLG5 Promotes Breast Cancer Malignancy by Inhibiting the Hippo Signaling Pathway. Scientific Reports, 7, Article No. 42125. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Qiao, X., Roth, I. and Féraille, E. (2014) Different Effects of ZO-1, ZO-2 and ZO-3 Silencing on Kidney Collecting Duct Principal Cell Proliferation and Adhesion. Cell Cycle (Georgetown, Tex.), 13, 3059-3075. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Liu, J., Li, J. and Ren, Y. (2014) DLG5 in Cell Polarity Maintenance and Cancer Development. International Journal of Biological Sciences, 10, 543-549. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Caunt, C.J., Sale, M.J. and Smith, P.D. (2015) MEK1 and MEK2 Inhibitors and Cancer Therapy: The Long and Winding Road. Nature Reviews. Cancer, 15, 577-592. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Zhan, L., Rosenberg, A. and Bergami, K.C. (2008) Deregulation of Scribble Promotes Mammary Tumorigenesis and Reveals a Role for Cell Polarity in Carcinoma. Cell, 135, 865-878. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Martin-Belmonte, F. and Perez-Moreno, M. (2011) Epithelial Cell Polarity, Stem Cells and Cancer. Nature Reviews. Cancer, 12, 23-38. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Pan, D. (2010) The Hippo Signaling Pathway in Development and Cancer. Developmental Cell, 19, 491-505. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Zhao, B., Lei, Q.Y. and Guan, K.L. (2008) The Hippo-YAP Pathway: New Connections between Regulation of Organ Size and Cancer. Current Opinion in Cell Biology, 20, 638-646. [Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
Grzeschik, N.A., Parsons, L.M. and Allott, M.L. (2010) Lgl, aPKC, and Crumbs Regulate the Salvador/Warts/Hippo Pathway through Two Distinct Mechanisms. Current Biol-ogy: CB, 20, 573-581. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Zhao, B., Wei, X.M., Li, W.Q., et al. (2007) Inactivation of YAP Oncoprotein by the Hippo Pathway Is Involved in Cell Contact Inhibition and Tissue Growth Control. Genes & Devel-opment, 21, 2747-2761.
https://pubmed.ncbi.nlm.nih.gov/17974916/
|
|
[70]
|
Sezaki, T., Inada, K., Sogabe, T., et al. (2012) Role of Dlg5/lp-dlg, a Membrane-Associated Guanylate Kinase Family Protein, in Epithelial-Mesenchymal Transition in LLc-PK1 Renal Epithelial Cells. PLOS ONE, 7, e35519.
https://pubmed.ncbi.nlm.nih.gov/22539977/
|
|
[71]
|
Neuzillet, C., Tijeras-Raballand, A. and Cohen, R. (2015) Tar-geting the TGFβ Pathway for Cancer Therapy. Pharmacology & Therapeutics, 147, 22-31. [Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
Asiedu, M.K., Ingle, J.N. and Behrens, M.D. (2011) TGF-beta/TNF(alpha)-Mediated Epithelial-Mesenchymal Transition Generates Breast Cancer Stem Cells with a Claudin-Low Phenotype. Cancer Research, 71, 4707-4719. [Google Scholar] [CrossRef]
|
|
[73]
|
Brabletz, T., Kalluri, R. and Nieto, M.A. (2018) EMT in Cancer. Nature Reviews. Cancer, 18, 128-134. [Google Scholar] [CrossRef] [PubMed]
|
|
[74]
|
Puisieux, A., Brabletz, T. and Caramel, J. (2014) Oncogenic Roles of EMT-Inducing Transcription Factors. Nature Cell Biology, 16, 488-494.
https://pubmed.ncbi.nlm.nih.gov/24875735/
|
|
[75]
|
Lamouille, S., Xu, J. and Derynck, R. (2014) Molecular Mecha-nisms of Epithelial-Mesenchymal Transition. Nature Reviews. Molecular Cell Biology, 15, 178-196. [Google Scholar] [CrossRef] [PubMed]
|
|
[76]
|
Chen, B., Yuan, Y. and Sun, L. (2020) MKL1 Mediates TGF-β Induced RhoJ Transcription to Promote Breast Cancer Cell Migration and Invasion. Frontiers in Cell and Developmental Biology, 8, Article No. 832. [Google Scholar] [CrossRef] [PubMed]
|